Meeting
2015 ASCO Annual Meeting
Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
Authors
Kohei Shitara
National Cancer Center Hospital East, Kashiwa, Japan
Kohei Shitara , Yasuhide Yamada , Kiyotaka Yoh , Yoichi Naito , Satoru Iwasa , Noboru Yamamoto , Anja von Heydebreck , Hiroyuki Achiwa , Toshihiko Doi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Clinical Trial Registration Number
NCT01943461
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3023)
DOI
10.1200/jco.2015.33.15_suppl.3023
Abstract #
3023
Poster Bd #
349
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.
First Author: Christopher Ryan Heery
Poster
2020 ASCO Virtual Scientific Program
Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.
First Author: Thorsten Oliver Goetze
Poster
2014 ASCO Annual Meeting
Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies.
First Author: Christopher Ryan Heery
Poster
2021 ASCO Annual Meeting
Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.
First Author: Thorsten Oliver Goetze